about
Development of polymeric micelles for targeting intractable cancersAntibody-drug conjugates--an emerging class of cancer treatmentCapturing Biological Activity in Natural Product Fragments by Chemical SynthesisModulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsComparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesAn overview of clinical and commercial impact of drug delivery systemsAntibody Drug Conjugates: Preclinical ConsiderationsChallenges and advances in the assessment of the disposition of antibody-drug conjugatesSortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo PotencyDevelopment and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerAntibody Therapies in Cancer.A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugateEnabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineeringImmunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesSynthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cellsAldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomesOrganocatalysts of oxidative protein folding inspired by protein disulfide isomerase.α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer.Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.Building better monoclonal antibody-based therapeutics.Antibody Drug Conjugates: Nonclinical Safety Considerations.High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody librariesAntibody Therapeutics in Oncology.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.Potential of antibody-drug conjugates and novel therapeutics in breast cancer management.Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.Industrial natural product chemistry for drug discovery and development.Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Natural product and natural product derived drugs in clinical trials.Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesNew horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.Stable and Potent Selenomab-Drug Conjugates.
P2860
Q26749611-86FC753B-E8DA-4074-AB70-4DA6EFF67AF9Q26770312-450DE2F8-E1A1-4385-9D2E-CA2AA4B66A11Q26772873-21120798-E4DB-402E-9689-09EFF8C0E2DDQ26781522-7771A19F-6047-4C5E-A971-043027DF813AQ26800175-4FDAA129-3D50-4AFA-A06D-1C42679A08A5Q26830923-87AD74D6-E17B-4CA2-B156-8C6BF294E488Q27007143-2709E573-D8C0-4553-8B85-EFF46AFE9EE4Q27022321-38BEF235-94A5-49A0-82CE-32A8EF03F41BQ28085074-E1923AAF-5F91-403F-A3B3-D88DFE28EDDCQ28546010-08998910-3266-4DB7-8996-A431B52A2CD0Q28552050-6DDB793A-8374-412B-AFA6-604EC80EBF4AQ31104000-1B46DD13-3E23-4E86-819B-56A5292896DDQ33574139-46E9E93C-8BF2-4F81-9023-97AC5E808B11Q33587970-2971776D-5543-400A-B584-1F2C567581D7Q33629621-A368A259-22A5-491D-89D3-FABFAF0222B0Q34045119-46874E4E-F58D-45E7-A9ED-66CFBD6D9EA6Q34408096-23B0EEFA-2894-4628-B43A-500F6928546AQ34434128-5E7428DA-C83C-4E78-8963-D7AA22DF6112Q35285491-566BB0C1-49A3-4B04-A55B-2952DBCD4179Q35652276-C39E6592-97BA-4DE1-940E-E49AA7659A15Q35691410-A77BACBA-1504-444E-BB98-0CDEB1B03A83Q35764587-481A66BC-8E17-4D5B-9EC6-E46E0590F32AQ35817552-8F3FCF08-D6CB-40EF-AA81-F693A1D8ACCDQ35967917-E917E940-9AA2-46D6-8449-59E789D83727Q36109883-50EECB38-8D20-4A6D-B556-C928DC9F86C9Q36791878-21C6731C-E807-4488-AB04-A31C263FF516Q37013285-708EBF72-46A0-4A61-906F-CB072C3AFA68Q37329842-655812EE-F5D7-4272-8944-CA093988BFF4Q37397674-48D5C3B5-46D5-444B-A36F-58DC8C24434CQ37593171-E0F4E633-2A35-4D81-9A6C-4935B8FD83A6Q37671599-31879F80-E4BC-4ABA-A86F-9453F7798051Q38129050-B15F306B-C9D6-47C4-B789-804DE53D3C87Q38154186-34AFF64F-C26D-4A54-8E6E-87BF70BBE465Q38247299-9A889B4C-090C-4C00-95AC-D9692E594CC5Q38247457-A825B26E-97E4-4EBB-B0E1-D6E1ECBD7509Q38275051-A50A4A53-FF37-4876-87BA-1EAE6A22F0ACQ38289992-B61C6A18-6BB5-4FE1-9422-068C3F1E13B9Q38350045-0CB5F003-98EA-4419-9F73-C6F8AC6EA388Q38355263-FD898B83-A9EE-414D-A5DC-4F6A63C507F3Q38432502-034EFD5C-7BC9-4409-AD6E-9440DD65DFDD
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Maturing antibody-drug conjugate pipeline hits 30.
@ast
Maturing antibody-drug conjugate pipeline hits 30.
@en
Maturing antibody-drug conjugate pipeline hits 30.
@nl
type
label
Maturing antibody-drug conjugate pipeline hits 30.
@ast
Maturing antibody-drug conjugate pipeline hits 30.
@en
Maturing antibody-drug conjugate pipeline hits 30.
@nl
prefLabel
Maturing antibody-drug conjugate pipeline hits 30.
@ast
Maturing antibody-drug conjugate pipeline hits 30.
@en
Maturing antibody-drug conjugate pipeline hits 30.
@nl
P356
P1476
Maturing antibody-drug conjugate pipeline hits 30.
@en
P2093
Asher Mullard
P2888
P304
P356
10.1038/NRD4009
P577
2013-05-01T00:00:00Z